Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2016 ASCO Annual Meeting /
Advanced hepatocellular carcinoma and personalised therapy

3rd - 7th Jun 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.16
Views: 2219

Dr Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Abou-alfa speaks with ecancertv at ASCO 2016 about novel treatments for advanced hepatocellular carcinoma.

Summarising two studies being presented at this year's conference, he introduces PHOCUS, trialling an oncolytic immunotherapy based on reprogrammed smallpox virus, and a phase I trial of monoclonal antibodies against HCC.

Both trials are currently recruiting participants.

For more on hepatocellular carcinoma, click here.

ecancer's filming at ASCO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation